Examples of using Macugen in English and their translations into German
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Financial
-
Ecclesiastic
-
Political
-
Computer
-
Programming
-
Official/political
-
Political
What MACUGEN contains.
Invented name Macugen.
What MACUGEN looks like and contents of the pack.
This improvement lasted for patients who were given Macugen for 2 years.
Macugen is not recommended during breast-feeding.
The safety and efficacy of Macugen beyond two years has not been demonstrated.
Macugen has not been studied in patients below the age of 18 years.
Sometimes, endophthalmitis(an infection inside the eye) can occur after Macugen treatment.
Macugen is a solution for intraocular injection injection into the eye.
Data over a two-year period indicate that Macugen treatment should be initiated as early as possible.
Macugen should be discarded if kept at room temperature for more than two weeks.
The symptoms you might experienceare described in Section 2 of this leaflet"Take special care with Macugen.
Macugen therapy administered to both eyes concurrently has not been studied.
The European Commission granteda marketing authorisation valid throughout the European Union, for Macugen to Pfizer Limited on 31 January 2006.
While Lucentis and Macugen are approved, Avastin is used off label.
Intravitreal injections for patients with maculardegeneration and other macular disorders Lucentis, Macugen, Avastin, Triamcinolon, Eyelea.
Macugen is used for the treatment of the wet form of age-related macular degeneration AMD.
After one year of treatment, the group of patients treated with Macugen 0.3 mg and 1 mg had less visual loss, compared with the group treated with usual care sham intervention.
Macugen has not been adequately studied in patients with creatinine clearance< 20 ml/ min.
If the solution appears cloudy, particles are observed or if there is evidence of damage to the syringe, or if the plastic clip is missing ornot attached to the syringe, Macugen should not be used.
The effects of Macugen 0.3 mg and 1 mg are almost identical, so the lower dose of 0.3 mg was approved.
American scientists Larry Gold andCraig Tuerk developed a process that led to the Macugen drug which slows or even halts‘wet' AMD.
Macugen should be inspected visually for particulate matter and discoloration prior to administration see section 6.6.
Two early clinical studies conducted in patients who received Macugen alone and in combination with PDT(photodynamic therapy) revealed no apparent difference in the plasma pharmacokinetics of pegaptanib.
Macugen works by inhibiting the growth of these abnormal blood vessels and by stemming the bleeding and leakage.
Treatment with Macugen is for intravitreal injection only and should be administered by ophthalmologists experienced in intravitreal injections.
Nevertheless, Macugen should be used during pregnancy only if the potential benefit to the mother justifies the potential risk to the foetus.
A direct relationship to Macugen or any of the various medications administered as part of the injection preparation procedure, or to other factors has not been established in these cases.
After 2 consecutive injections of Macugen, if a patient does not demonstrate a treatment benefit(loss of less than 15 letters of visual acuity) at the 12-week visit, consideration should be given to stopping or withholding Macugen therapy.
The company that makes Macugen will provide education for doctors(to minimise the risks associated with the injection in the eye) and for patients so they can recognise any serious side effects, and know when to seek urgent attention from their doctor.